Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis

Bajaj, Jasmohan S., Khoruts, Alexander · 2020 · Journal of Hepatology

Abstract

Patients with chronic liver disease and cirrhosis demonstrate a global mucosal immune impairment, which is associated with altered gut microbiota composition and functionality. These changes progress along with the advancing degree of cirrhosis and can be linked with hepatic encephalopathy, infections and even prognostication independent of clinical biomarkers. Along with compositional changes, microbial functional alterations focused on short-chain fatty acids, bioenergetics and bile acid metabolism are also associated with cirrhosis progression and outcomes. Altering the microbial functional and structural profile is partly achieved by medications used in patients with cirrhosis such as rifaximin, lactulose, proton pump inhibitors and other antibiotics. However, the role of fecal or intestinal microbiota transplantation is being increasingly recognized. The challenges, opportunities and the road ahead for the appropriate and safe use of intestinal microbiota transplantation in liver disease are reviewed, which opens up an exciting field of investigation and therapy in cirrhosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.01.017

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 142

  1. Wiest, 2017, Targeting the gut-liver axis in liver disease, J Hepatol, 67, 1084, 10.1016/j.jhep.2017.05.007 · DOI · Paper page
  2. Allaband, 2019, Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians, Clin Gastroenterol Hepatol, 17, 218, 10.1016/j.cgh.2018.09.017 · DOI · Paper page
  3. Acharya, 2019, Altered microbiome in patients with cirrhosis and complications, Clin Gastroenterol Hepatol, 17, 307, 10.1016/j.cgh.2018.08.008 · DOI · Paper page
  4. Asrani, 2019, Burden of liver diseases in the world, J Hepatol, 70, 151, 10.1016/j.jhep.2018.09.014 · DOI · Paper page
  5. Bajaj, 2019, Alcohol, liver disease and the gut microbiota, Nat Rev Gastroenterol Hepatol, 16, 235, 10.1038/s41575-018-0099-1 · DOI · Paper page
  6. Hatton, 2019, Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?, Expert Rev Gastroenterol Hepatol, 13, 1, 10.1080/17474124.2019.1543587 · DOI
  7. Khoruts, 2019, Fecal microbiota transplant: a rose by any other name, Am J Gastroenterol, 114, 1176, 10.14309/ajg.0000000000000286 · DOI
  8. Yang, 2017, Intestinal fungi contribute to development of alcoholic liver disease, J Clin Invest, 127, 2829, 10.1172/JCI90562 · DOI · Paper page
  9. Bajaj, 2017, Continued alcohol misuse in human cirrhosis is associated with an impaired gut-liver axis, Alcohol Clin Exp Res, 41, 1857, 10.1111/acer.13498 · DOI
  10. Llopis, 2016, Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease, Gut, 65, 830, 10.1136/gutjnl-2015-310585 · DOI · Paper page
  11. Pinzone, 2012, Microbial translocation in chronic liver diseases, Int J Microbiol, 2012, 694629, 10.1155/2012/694629 · DOI
  12. Young, 2017, The role of the microbiome in human health and disease: an introduction for clinicians, BMJ, 356, j831, 10.1136/bmj.j831 · DOI · Paper page
  13. Sookoian, 2020, Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease, Gut, 10.1136/gutjnl-2019-318811 · DOI · Paper page
  14. Hornung, 2019, Response to: ‘Circulating microbiome in blood of different circulatory compartments' by Schierwagen et al, Gut
  15. Loomba, 2019, Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease, Cell Metab, 30, 607, 10.1016/j.cmet.2019.08.002 · DOI · Paper page
  16. Wei, 2019, Alterations of gut microbiome in autoimmune hepatitis, Gut, 69, 569, 10.1136/gutjnl-2018-317836 · DOI · Paper page
  17. Kummen, 2017, The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls, Gut, 66, 611, 10.1136/gutjnl-2015-310500 · DOI · Paper page
  18. Ruhlemann, 2017, Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis, Gut, 66, 753, 10.1136/gutjnl-2016-312180 · DOI
  19. Pereira, 2017, Bile microbiota in primary sclerosing cholangitis: impact on disease progression and development of biliary dysplasia, PLoS One, 12, e0182924, 10.1371/journal.pone.0182924 · DOI
  20. Inoue, 2018, Gut dysbiosis associated with hepatitis C virus infection, Clin Infect Dis, 67, 869, 10.1093/cid/ciy205 · DOI · Paper page
  21. Preveden, 2017, Gut microbiota changes and chronic hepatitis C virus infection, Expert Rev Gastroenterol Hepatol, 11, 813, 10.1080/17474124.2017.1343663 · DOI
  22. Heidrich, 2018, Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls, Liver Int, 38, 50, 10.1111/liv.13485 · DOI
  23. Lu, 2011, Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients, Microb Ecol, 61, 693, 10.1007/s00248-010-9801-8 · DOI · Paper page
  24. Wei, 2013, Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach, BMC Gastroenterol, 13, 175, 10.1186/1471-230X-13-175 · DOI
  25. Bajaj, 2019, Gut microbiota as biosensors in patients with cirrhosis, Cell Mol Gastroenterol Hepatol, 8, 231, 10.1016/j.jcmgh.2019.04.016 · DOI
  26. D'Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, J Hepatol, 44, 217, 10.1016/j.jhep.2005.10.013 · DOI · Paper page
  27. Arvaniti, 2010, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, 139, 1246, 10.1053/j.gastro.2010.06.019 · DOI · Paper page
  28. Puri, 2018, The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis, Hepatology, 67, 1284, 10.1002/hep.29623 · DOI
  29. Duan, 2019, Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease, Nature, 575, 505, 10.1038/s41586-019-1742-x · DOI · Paper page
  30. Ciocan, 2018, Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis, Aliment Pharmacol Ther, 48, 961, 10.1111/apt.14949 · DOI
  31. Tandon, 2008, Bacterial infections, sepsis, and multiorgan failure in cirrhosis, Semin Liver Dis, 28, 26, 10.1055/s-2008-1040319 · DOI · Paper page
  32. Di Lorenzo, 2019, Lipopolysaccharide structures of Gram-negative populations in the gut microbiota and effects on host interactions, FEMS Microbiol Rev, 43, 257, 10.1093/femsre/fuz002 · DOI · Paper page
  33. Bajaj, 2018, Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis, Am J Gastroenterol, 113, 1177, 10.1038/s41395-018-0085-9 · DOI
  34. Chen, 2011, Characterization of fecal microbial communities in patients with liver cirrhosis, Hepatology, 54, 562, 10.1002/hep.24423 · DOI · Paper page
  35. Bajaj, 2012, Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation, Am J Physiol Gastrointest Liver Physiol, 303, G675, 10.1152/ajpgi.00152.2012 · DOI · Paper page
  36. Bajaj, 2019, Alterations in skin microbiomes of patients with cirrhosis, Clin Gastroenterol Hepatol, 17, 2581, 10.1016/j.cgh.2019.03.028 · DOI
  37. Vilstrup, 2014, Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, Hepatology, 60, 715, 10.1002/hep.27210 · DOI · Paper page
  38. Patidar, 2014, Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization, Am J Gastroenterol, 109, 1757, 10.1038/ajg.2014.264 · DOI · Paper page
  39. Kang, 2016, Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice, Hepatology, 64, 1232, 10.1002/hep.28696 · DOI
  40. Sarma, 2011, Multi-dimensional MR spectroscopy: towards a better understanding of hepatic encephalopathy, Metab Brain Dis, 26, 173, 10.1007/s11011-011-9250-1 · DOI
  41. Ahluwalia, 2016, Impaired gut-liver-brain axis in patients with cirrhosis, Sci Rep, 6, 26800, 10.1038/srep26800 · DOI · Paper page
  42. Zhang, 2013, Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing, Am J Gastroenterol, 108, 1601, 10.1038/ajg.2013.221 · DOI · Paper page
  43. Bajaj, 2019, Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis, Clin Gastroenterol Hepatol, 17, 756, 10.1016/j.cgh.2018.07.022 · DOI
  44. Shen, 2015, Engineering the gut microbiota to treat hyperammonemia, J Clin Invest, 125, 2841, 10.1172/JCI79214 · DOI · Paper page
  45. Zullo, 2003, Hepatic encephalopathy and Helicobacter pylori: a critical reappraisal, J Clin Gastroenterol, 37, 164, 10.1097/00004836-200308000-00014 · doi:10.1097/00004836-200308000-00014
  46. Bajaj, 2019, Posttraumatic stress disorder is associated with altered gut microbiota that modulates cognitive performance in veterans with cirrhosis, Am J Physiol Gastrointest Liver Physiol, 317, G661, 10.1152/ajpgi.00194.2019 · DOI
  47. Nava, 2011, Diversity of the autochthonous colonic microbiota, Gut Microbes, 2, 10.4161/gmic.2.2.15416 · DOI · Paper page
  48. Wikoff, 2009, Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites, Proc Natl Acad Sci U S A, 106, 3698, 10.1073/pnas.0812874106 · DOI · Paper page
  49. Bajaj, 2012, A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy, Metab Brain Dis, 27, 205, 10.1007/s11011-012-9303-0 · DOI
  50. Ridlon, 2016, Consequences of bile salt biotransformations by intestinal bacteria, Gut Microbes, 7, 22, 10.1080/19490976.2015.1127483 · DOI · Paper page
  51. Nardelli, 2019, Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis, Hepatology, 70, 640, 10.1002/hep.30304 · DOI · Paper page
  52. Bajaj, 2014, Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function, Am J Physiol Gastrointest Liver Physiol, 307, G951, 10.1152/ajpgi.00268.2014 · DOI · Paper page
  53. Bajaj, 2018, Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis, Am J Gastroenterol, 113, 1177, 10.1038/s41395-018-0085-9 · DOI
  54. Sarangi, 2017, Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration, BMC Gastroenterol, 17, 125, 10.1186/s12876-017-0683-9 · DOI
  55. Wang, 2019, Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial, J Dig Dis, 20, 547
  56. Bass, 2010, Rifaximin treatment in hepatic encephalopathy, N Engl J Med, 362, 1071, 10.1056/NEJMoa0907893 · DOI · Paper page
  57. Kang, 2016, Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition, Clin Transl Gastroenterol, 7, e187, 10.1038/ctg.2016.44 · DOI
  58. Wu, 2012, Changes of gut bacteria and immune parameters in liver transplant recipients, Hepatobiliary Pancreat Dis Int, 11, 40, 10.1016/S1499-3872(11)60124-0 · DOI
  59. Zhang, 2018, Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice, Am J Transplant, 18, 1646, 10.1111/ajt.14661 · DOI
  60. Bajaj, 2017, Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis, Liver Transpl, 23, 907, 10.1002/lt.24754 · DOI
  61. Annavajhala, 2019, Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation, Nat Commun, 10, 4715, 10.1038/s41467-019-12633-4 · DOI
  62. Bajaj, 2018, Alterations in gut microbial function following liver transplant, Liver Transpl, 24, 752, 10.1002/lt.25046 · DOI
  63. Bajaj, 2007, Testing for minimal hepatic encephalopathy in the United States: an AASLD survey, Hepatology, 45, 833, 10.1002/hep.21515 · doi:10.1002/hep.21515
  64. Bajaj, 2019, Specific gut and salivary microbiota patterns are linked with different cognitive testing strategies in minimal hepatic encephalopathy, Am J Gastroenterol, 114, 1080, 10.14309/ajg.0000000000000102 · DOI
  65. Kamath, 2007, The model for end-stage liver disease (MELD), Hepatology, 45, 797, 10.1002/hep.21563 · DOI · Paper page
  66. Bajaj, 2018, Fungal dysbiosis in cirrhosis, Gut, 67, 1146, 10.1136/gutjnl-2016-313170 · DOI · Paper page
  67. Bajaj, 2018, Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis, JCI Insight, 3, 10.1172/jci.insight.98019 · DOI
  68. Zhang, 2019, Characterization of the circulating microbiome in acute-on-chronic liver failure associated with hepatitis B, Liver Int, 39, 1207, 10.1111/liv.14097 · DOI
  69. Chen, 2015, Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality, J Gastroenterol Hepatol, 30, 1429, 10.1111/jgh.12932 · DOI · Paper page
  70. Bajaj, 2019, Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis, Clin Gastroenterol Hepatol, 17, 756, 10.1016/j.cgh.2018.07.022 · DOI
  71. Duseja, 2019, High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study, BMJ Open Gastroenterol, 6, e000315, 10.1136/bmjgast-2019-000315 · DOI
  72. Damman, 2018, Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis, Aliment Pharmacol Ther, 47, 886, 10.1111/apt.14540 · DOI
  73. Eiseman, 1958, Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis, Surgery, 44, 854
  74. Oren, 2018, Clostridium difficile and Clostridioides difficile: two validly published and correct names, Anaerobe, 52, 125, 10.1016/j.anaerobe.2018.07.005 · DOI
  75. Kelly, 2008, Clostridium difficile–more difficult than ever, N Engl J Med, 359, 1932, 10.1056/NEJMra0707500 · DOI · Paper page
  76. Ma, 2017, Increasing incidence of multiply recurrent Clostridium difficile Infection in the United States: a cohort study, Ann Intern Med, 167, 152, 10.7326/M16-2733 · DOI · Paper page
  77. Bakken, 2011, Treating Clostridium difficile infection with fecal microbiota transplantation, Clin Gastroenterol Hepatol, 9, 1044, 10.1016/j.cgh.2011.08.014 · DOI · Paper page
  78. Jorgensen, 2019, Banking feces: a new frontier for public blood banks?, Transfusion, 59, 2776, 10.1111/trf.15422 · DOI
  79. Costello, 2012, The application of ecological theory toward an understanding of the human microbiome, Science, 336, 1255, 10.1126/science.1224203 · DOI · Paper page
  80. Khoruts, 2015, Development of fecal microbiota transplantation suitable for mainstream medicine, Clin Gastroenterol Hepatol, 13, 246, 10.1016/j.cgh.2014.11.014 · DOI
  81. Hamilton, 2012, Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection, Am J Gastroenterol, 107, 761, 10.1038/ajg.2011.482 · DOI · Paper page
  82. Weingarden, 2015, Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection, Microbiome, 3, 10, 10.1186/s40168-015-0070-0 · DOI · Paper page
  83. Youngster, 2014, Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection, JAMA, 312, 1772, 10.1001/jama.2014.13875 · DOI · Paper page
  84. Goldenberg, 2018, Comparison of different strategies for providing fecal microbiota transplantation to treat patients with recurrent Clostridium difficile infection in two English hospitals: a review, Infect Dis Ther, 7, 71, 10.1007/s40121-018-0189-y · DOI
  85. Bajaj, 2017, Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial, Hepatology, 66, 1727, 10.1002/hep.29306 · DOI · Paper page
  86. Teigen, 2019, Dietary factors in sulfur metabolism and pathogenesis of ulcerative colitis, Nutrients, 11, 10.3390/nu11040931 · DOI
  87. Martinez-Guryn, 2019, Regional diversity of the gastrointestinal microbiome, Cell Host Microbe, 26, 314, 10.1016/j.chom.2019.08.011 · DOI · Paper page
  88. Holmes, 2012, Therapeutic modulation of microbiota-host metabolic interactions, Sci Transl Med, 4, 137rv136, 10.1126/scitranslmed.3004244 · DOI · Paper page
  89. Robertson, 2019, Comparison of co-housing and littermate methods for microbiota standardization in mouse models, Cell Rep, 27, 1910, 10.1016/j.celrep.2019.04.023 · DOI · Paper page
  90. Costello, 2019, Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial, JAMA, 321, 156, 10.1001/jama.2018.20046 · DOI · Paper page
  91. Kang, 2017, Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study, Microbiome, 5, 10, 10.1186/s40168-016-0225-7 · DOI · Paper page
  92. Jalanka, 2016, Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection, BMC Med, 14, 155, 10.1186/s12916-016-0698-z · DOI
  93. Staley, 2017, Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study, Am J Gastroenterol, 112, 940, 10.1038/ajg.2017.6 · DOI · Paper page
  94. Staley, 2017, Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota, Gut microbes, 8, 276, 10.1080/19490976.2017.1299310 · DOI
  95. Staley, 2019, Durable long-term bacterial engraftment following encapsulated fecal microbiota transplantation to treat Clostridium difficile infection, mBio, 10, 10.1128/mBio.01586-19 · DOI
  96. Manichanh, 2010, Reshaping the gut microbiome with bacterial transplantation and antibiotic intake, Genome Res, 20, 1411, 10.1101/gr.107987.110 · DOI · Paper page
  97. Vujkovic-Cvijin, 2017, Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals, Gut microbes, 8, 440, 10.1080/19490976.2017.1334034 · DOI
  98. Jalanka, 2015, Effects of bowel cleansing on the intestinal microbiota, Gut, 64, 1562, 10.1136/gutjnl-2014-307240 · DOI · Paper page
  99. Comeau, 2007, Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth, PLoS One, 2, e799, 10.1371/journal.pone.0000799 · DOI
  100. Maiques, 2006, beta-lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in Staphylococcus aureus, J Bacteriol, 188, 2726, 10.1128/JB.188.7.2726-2729.2006 · DOI · Paper page
  101. Antharam, 2016, An integrated metabolomic and microbiome analysis identified specific gut microbiota associated with fecal cholesterol and coprostanol in Clostridium difficile infection, PLoS One, 11, e0148824, 10.1371/journal.pone.0148824 · DOI
  102. Nusbaum, 2018, Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients, FEMS Microbiol Ecol, 94, 10.1093/femsec/fiy133 · DOI
  103. Seekatz, 2018, Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection, Anaerobe, 53, 64, 10.1016/j.anaerobe.2018.04.001 · DOI · Paper page
  104. Khoruts, 2016, Understanding the mechanisms of faecal microbiota transplantation, Nat Rev Gastroenterol Hepatol, 13, 508, 10.1038/nrgastro.2016.98 · DOI · Paper page
  105. Staley, 2018, Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation, Microbiome, 6, 166, 10.1186/s40168-018-0549-6 · DOI
  106. Khanna, 2017, Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease, Microbiome, 5, 55, 10.1186/s40168-017-0269-3 · DOI · Paper page
  107. Newman, 2017, Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease, Gut microbes, 8, 303, 10.1080/19490976.2017.1279377 · DOI
  108. Pringle, 2019, Patients with cirrhosis require more fecal microbiota capsules to cure refractory and recurrent Clostridium difficile infections, Clin Gastroenterol Hepatol, 17, 791, 10.1016/j.cgh.2018.05.038 · DOI
  109. Kao, 2016, Fecal microbiota transplantation in the management of hepatic encephalopathy, Hepatology, 63, 339, 10.1002/hep.28121 · DOI
  110. Bajaj, 2018, Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant, Hepatology, 68, 1549, 10.1002/hep.30037 · DOI
  111. Bajaj, 2019, Long-term outcomes after fecal microbiota transplantation in cirrhosis, Gastroenterology, 156, 1921, 10.1053/j.gastro.2019.01.033 · DOI · Paper page
  112. Liu, 2020, Neuroinflammation in murine cirrhosis is dependent on the gut microbiome and is attenuated by fecal transplant, Hepatology, 71, 611, 10.1002/hep.30827 · DOI
  113. Bajaj, 2019, Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial, Hepatology, 70, 1690, 10.1002/hep.30690 · DOI · Paper page
  114. Bajaj, 2019, Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis, JCI Insight, 4, 10.1172/jci.insight.133410 · DOI
  115. Kassam, 2019, Donor screening for fecal microbiota transplantation, N Engl J Med, 381, 2070, 10.1056/NEJMc1913670 · DOI
  116. Ren, 2017, Faecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy, Hepatology, 65, 1765, 10.1002/hep.29008 · DOI · Paper page
  117. Philips, 2017, Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study, Clin Gastroenterol Hepatol, 15, 600, 10.1016/j.cgh.2016.10.029 · DOI · Paper page
  118. Philips, 2018, Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis, Indian J Gastroenterol, 37, 215, 10.1007/s12664-018-0859-4 · DOI
  119. Djulbegovic, 2011, Uncertainty and equipoise: at interplay between epistemology, decision making and ethics, Am J Med Sci, 342, 282, 10.1097/MAJ.0b013e318227e0b8 · DOI
  120. Kakiyama, 2013, Modulation of the fecal bile acid profile by gut microbiota in cirrhosis, J Hepatol, 58, 949, 10.1016/j.jhep.2013.01.003 · DOI · Paper page
  121. Bajaj, 2018, Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort, Hepatology, 68, 234, 10.1002/hep.29791 · DOI · Paper page
  122. Cox, 2020, Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis, Liver Int, 40, 416, 10.1111/liv.14256 · DOI
  123. Tuomisto, 2014, Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics, BMC Gastroenterol, 14, 40, 10.1186/1471-230X-14-40 · DOI
  124. Bajaj, 2015, Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus, Sci Rep, 5, 18559, 10.1038/srep18559 · DOI
  125. Santiago, 2016, Alteration of the serum microbiome composition in cirrhotic patients with ascites, Sci Rep, 6, 25001, 10.1038/srep25001 · DOI
  126. Iebba, 2018, Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy, Sci Rep, 8, 8210, 10.1038/s41598-018-26509-y · DOI
  127. Jacobs, 2018, Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: the microbiome, microbial markers and liver disease study, Hepatol Res, 48, 1108, 10.1111/hepr.13207 · DOI
  128. Schierwagen, 2019, Circulating microbiome in blood of different circulatory compartments, Gut, 68, 578, 10.1136/gutjnl-2018-316227 · DOI
  129. Raj, 2019, Dysbiosis of the duodenal mucosal microbiota is associated with increased small intestinal permeability in chronic liver disease, Clin Transl Gastroenterol, 10, e00068, 10.14309/ctg.0000000000000068 · DOI
  130. Bajaj, 2019, Alterations in skin microbiomes of patients with cirrhosis, Clin Gastroenterol Hepatol, 17, 2581, 10.1016/j.cgh.2019.03.028 · DOI
  131. Chen, 2015, Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality, J Gastroenterol Hepatol, 30, 1429, 10.1111/jgh.12932 · DOI · Paper page
  132. Ahluwalia, 2012, Rifaximin improves brain edema and working memory in minimal hepatic encephalopathy: a prospective fMRI study, Hepatology, 56, 162A
  133. Kaji, 2017, Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity, World J Gastroenterol, 23, 8355, 10.3748/wjg.v23.i47.8355 · DOI
  134. Schulz, 2019, Long-term effect of rifaximin with and without lactulose on the active bacterial assemblages in the proximal small bowel and faeces in patients with minimal hepatic encephalopathy, Dig Dis, 37, 161, 10.1159/000494216 · doi:10.1159/000494216
  135. Horvath, 2019, Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis, Sci Rep, 9, 12000, 10.1038/s41598-019-48352-5 · DOI · Paper page
  136. Bajaj, 2014, Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis, Aliment Pharmacol Ther, 39, 1113, 10.1111/apt.12695 · DOI · Paper page
  137. Xia, 2018, Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis, J Int Med Res, 46, 3596
  138. Acharya, 2017, Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis, Aliment Pharmacol Ther, 45, 319, 10.1111/apt.13858 · DOI · Paper page
  139. Bajaj, 2018, Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis, Am J Physiol Gastrointest Liver Physiol, 315, G824, 10.1152/ajpgi.00230.2018 · DOI
  140. Bajaj, 2017, Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial, Hepatology, 66, 1727, 10.1002/hep.29306 · DOI · Paper page
  141. Bajaj, 2019, Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis, Gastroenterology, 156, 1921, 10.1053/j.gastro.2019.01.033 · DOI · Paper page
  142. Mehta, 2018, Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series, Indian J Gastroenterol, 37, 559, 10.1007/s12664-018-0906-1 · DOI

Cited by

See all 167

Metadata

Authors
Bajaj, J. S., & Khoruts, A.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-05
Volume
72
Issue
5
Pages
1003-1027
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3003277102
Cited by
167
References
46
FWCI
7.47
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Center for Advancing Translational Sciences
  • Agency for Healthcare Research and Quality
  • VHA Office of Research and Development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. https://app.cochat.ai/papers/10.1016/j.jhep.2020.01.017
The paper
Bajaj, J. S., & Khoruts, A. (2020). Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.01.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.